(2S)-N-(2-oxoethyl)pyrrolidine-2-carboxamide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S)-N-(2-oxoethyl)pyrrolidine-2-carboxamide
• 化学式: C₇H₁₂N₂O₂
• 分子量: 156.18
• InChiKey: YKHSOLCASGJBIK-LURJTMIESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  58.2
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• Prodrugs of riluzole and their method of use
  申请人：Biohaven Pharmaceutical Holding Company Ltd.

  公开号：US10639298B2

  公开（公告）日：2020-05-05

  Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.

  本发明的药物组合物包括取代的利鲁唑原药，可通过释放利鲁唑治疗癌症，包括黑色素瘤、乳腺癌、脑癌和前列腺癌。利鲁唑原药对肝脏代谢的稳定性增强，通过口服进入全身循环，然后通过酶或一般生物物理释放过程裂解，在血浆中释放利鲁唑。
• Catalytic Asymmetric Synthesis of Optically Active Alpha-Halo-Carbonyl Compounds
  申请人：Halland Nis

  公开号：US20070276142A1

  公开（公告）日：2007-11-29

  A process for the catalytic asymmetric synthesis of an optically active compound of the formula (1a) or (1b) wherein R is an organic group; X is halogen; R 1 and R 2 which may the same or different represents H, or an organic group or R 1 and R 2 may be bridged together forming part of a ring system; R and R 2 may be bridged together forming part of a ring system; with the provisio that R and R 1 are different and R 2 , when different from H, is attached though a carbon-carbon bond, comprising the step of reacting a compound of the formula (2) with a halogenation agent in the presence of a catalytic amount of a chiral nitrogen containing organic compound.
• SELECTIVE DELIVERY MOLECULES AND METHODS OF USE
  申请人：Liu Junjie

  公开号：US20150031852A1

  公开（公告）日：2015-01-29

  Disclosed herein is a selective delivery molecule comprising: (a) an acidic sequence (portion A) which is effective to inhibit or prevent the uptake into cells or tissue retention, (b) a molecular transport or retention sequence (portion B), and (c) a linker between portion A and portion B, and (d) at least one cargo moiety.
• PRODRUGS RILUZOLE AND THEIR METHOD OF USE
  申请人：Biohaven Pharmaceutical Holding Company Ltd.

  公开号：US20180037557A1

  公开（公告）日：2018-02-08

  Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.
• US9278144B2
  申请人：——

  公开号：US9278144B2

  公开（公告）日：2016-03-08